Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers

NCT00351767 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00351767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00351767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
Not reported
Enrollment
170 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

foot ulcer, diabetic